Literature DB >> 3461147

Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure.

S P Andreoli, J H Clark, W A McGuire, J M Bergstein.   

Abstract

We measured serial urine levels of hypoxanthine, xanthine, and uric acid in 19 children with acute lymphocytic leukemia (ALL) receiving allopurinol therapy during tumor lysis; four of these children developed acute renal failure. The urinary excretion of uric acid rose moderately from 447 +/- 251 micrograms/dl glomerular filtrate before chemotherapy to 778 +/- 463 micrograms/dl glomerular filtrate during tumor lysis (P less than 0.05) whereas the urinary excretion of hypoxanthine (17.9 +/- 15 to 292 +/- 213 micrograms/dl glomerular filtrate) and xanthine (74 +/- 62 to 1091 +/- 1085 micrograms/dl glomerular filtrate) rose dramatically (P less than 0.001). The urinary excretion of uric acid, hypoxanthine, and xanthine per deciliter of filtrate was significantly higher (P less than 0.001) in those who developed acute renal failure than in those who did not, but the highest urine concentration of these purine metabolites did not differ in the two groups. In all 19 children, the highest urine concentration of uric acid and hypoxanthine during tumor lysis did not exceed the solubility limit of each in an alkaline urine specimen. In contrast, the peak urine concentration of xanthine exceeded its solubility limit in an alkaline urine specimen in 16 of 19 children. The urine sediment during the period of tumor lysis was examined by diffuse reflectance infrared spectroscopy; precipitated xanthine was found in sediment from eight of the 19 children, was significantly (P less than 0.001) associated with a urine xanthine level greater than 350 mg/dL, and occurred with equal frequency in those who did or did not develop acute renal failure. We conclude that urinary excretion of hypoxanthine and xanthine increases dramatically whereas uric acid excretion rises moderately in children undergoing tumor lysis while receiving allopurinol, that acute renal failure occurs in children with a higher purine load per deciliter of glomerular filtrate, but that factors other than tubular precipitation of purine metabolites are likely to be involved in the pathogenesis of renal failure during tumor lysis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3461147     DOI: 10.1016/s0022-3476(86)80387-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  Pharmacodynamic analysis of intravenous recombinant urate oxidase using an indirect pharmacological response model in healthy subjects.

Authors:  Ning-fang Cai; Ze-neng Cheng; Ying Zi; Xi Luo; Xin Guo; Zhi Liu; Li-yun Zheng
Journal:  Acta Pharmacol Sin       Date:  2014-10-06       Impact factor: 6.150

2.  Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

Authors:  Jorge Cortes; Joseph O Moore; Richard T Maziarz; Meir Wetzler; Michael Craig; Jeffrey Matous; Selina Luger; Bimalangshu R Dey; Gary J Schiller; Dat Pham; Camille N Abboud; Muthuswamy Krishnamurthy; Archie Brown; Abderrahmane Laadem; Karen Seiter
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

3.  Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.

Authors:  Kristine R Crews; Yinmei Zhou; Jennifer L Pauley; Scott C Howard; Sima Jeha; Mary V Relling; Ching-Hon Pui
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

4.  Rasburicase improves hyperuricemia in infants with acute kidney injury.

Authors:  David J Hobbs; Julia M Steinke; Jin Y Chung; Gina-Marie Barletta; Timothy E Bunchman
Journal:  Pediatr Nephrol       Date:  2009-11-21       Impact factor: 3.714

Review 5.  Tumor lysis syndrome: pathogenesis and management.

Authors:  D P Jones; H Mahmoud; R W Chesney
Journal:  Pediatr Nephrol       Date:  1995-04       Impact factor: 3.714

Review 6.  Acute kidney injury in children.

Authors:  Sharon Phillips Andreoli
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

7.  Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).

Authors:  Andrea Pession; Fraia Melchionda; Claudia Castellini
Journal:  Biologics       Date:  2008-03

8.  Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2020-11-27       Impact factor: 3.714

9.  Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome.

Authors:  Mihoko Takai; Takahiro Yamauchi; Kei Fujita; Shin Lee; Miyuki Ookura; Shinji Kishi; Yoshimasa Urasaki; Akira Yoshida; Hiromichi Iwasaki; Takanori Ueda
Journal:  Oncol Lett       Date:  2014-07-30       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.